高级检索
刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 江伟, 顾雯雯, 张小平. 杭州市2019 — 2021年灭活流感疫苗疑似预防接种异常反应监测[J]. 中国公共卫生, 2022, 38(10): 1322-1326. DOI: 10.11847/zgggws1138167
引用本文: 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 江伟, 顾雯雯, 张小平. 杭州市2019 — 2021年灭活流感疫苗疑似预防接种异常反应监测[J]. 中国公共卫生, 2022, 38(10): 1322-1326. DOI: 10.11847/zgggws1138167
shu
LIU Yan, DU Jian, XU Yu-yang, . Adverse events following immunization with inactivated influenza vaccine in Hangzhou, 2019 – 2021: a surveillance data analysis[J]. Chinese Journal of Public Health, 2022, 38(10): 1322-1326. DOI: 10.11847/zgggws1138167
Citation: LIU Yan, DU Jian, XU Yu-yang, . Adverse events following immunization with inactivated influenza vaccine in Hangzhou, 2019 – 2021: a surveillance data analysis[J]. Chinese Journal of Public Health, 2022, 38(10): 1322-1326. DOI: 10.11847/zgggws1138167
shu

杭州市2019 — 2021年灭活流感疫苗疑似预防接种异常反应监测

Adverse events following immunization with inactivated influenza vaccine in Hangzhou, 2019 – 2021: a surveillance data analysis

    摘要
  • 摘要:
      目的  分析浙江省杭州市2019 — 2021年灭活流感疫苗（IIV）接种后疑似预防接种异常反应（AEFI）发生特征。
      方法  通过浙江省疫苗和预防接种综合管理信息系统和全国AEFI信息管理系统收集2019 — 2021年IIV接种情况和AEFI报告个案，描述性分析IIV接种后AEFI报告发生率。
      结果  2019 — 2021年杭州市报告IIV AEFI个案568例，报告发生率为40.48/10万剂；其中一般反应和异常反应报告发生率分别为34.70/10万剂（487例）、3.42/10万剂（48例）。 < 3、3～17、18～59和 ≥ 60岁人群接种IIV AEFI的发生率分别为88.71/10万剂（180例）、51.11/10万剂（162例）、38.87/10万剂（74例）、21.93/10万剂（152例）。接种4价IIV（IIV4）后局部红肿和局部硬结的发生率（25.64、14.13/10万剂）均高于接种3价IIV（IIV3）（9.30、5.19/10万剂）（P < 0.05），异常反应发生率均无显著性差异（P > 0.05）。
      结论  杭州市2019 — 2021年IIV AEFI报告发生率较低，IIV3和IIV4均具有良好的安全性。

     

    Abstract:
      Objective  To analyze the incidence and characteristics of adverse events following immunization (AEFIs) with vaccination of inactivated influenza vaccine (IIV) during 2019 – 2021 in Hangzhou city, Zhejiang province, China.
      Methods  Data about IIV vaccination and IIV AEFI was collected from the Zhejiang Information System for Immunization Program and the National AEFI Information System. A descriptive analysis on the reported incidence of IIV AEFI was conducted.
      Results  A total of 568 IIV AEFI cases were reported and the reported incidence rate (1/per 100 000 doses administered) was 40.48 during 2019 – 2021 in the city. The reported incidence rate (1/per 100 000 doses administered) was 34.70 (487 cases) and 3.42 (48 cases) for common and rare adverse reactions. The reported incidence rate were 88.71 (180 cases), 51.11 (162 cases), 38.87 (74 cases), and 21.93 (152 cases) for the vaccine recipients aged < 3, 3 – 17, 18 – 59, and ≥ 60 years, respectively. Compared to those among the recipients of trivalent IIV (IIV3), significantly higher incidence rate (1/per 100 000 doses administered) of local swelling (25.64 vs. 14.13) and induration (9.30 vs. 5.19) were reported among the recipients of tetravalent IIV (IIV4) (both P < 0.05). But no significant difference in overall incidence of AEFIs was observed between IIV3 and IIV4 (P > 0.05).
      Conclusion  The reported incidence of IIV AEFI was low during 2019 – 2021 in Hangzhou city, indicating a good safety of IIV3 and IIV4 vaccination.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回